Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 12, 2011 08:00 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Pharmaceuticals to Present at UBS Conference

CAMBRIDGE, Mass., Sept. 12, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) will be presenting at UBS Global Life Sciences Conference on Monday, September 19, 2011 at 2:00 p.m....
August 30, 2011 16:00 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Pharmaceuticals to Present at Two Upcoming Conferences

CAMBRIDGE, Mass., Aug. 30, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) will be presenting at the Stifel Nicolaus Healthcare Conference on Wednesday, September 7, 2011 at...
August 09, 2011 16:00 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Reports Second Quarter 2011 Financial Results

CAMBRIDGE, Mass., Aug. 9, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today highlighted its recent clinical and business progress and announced its second quarter 2011...
August 02, 2011 08:00 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Announces the Date of Its Second Quarter 2011 Financial Results Conference Call and Webcast

CAMBRIDGE, Mass., Aug. 2, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) will host a conference call on Tuesday, August 9, 2011 at 4:30 p.m. ET. During the call, management will...
June 22, 2011 10:00 ET | Source: Infinity Pharmaceuticals, Inc.

Photo Release -- Biopharmaceutical Company Seeks New Sources of Corn Lily

SALT LAKE CITY and BOISE, Idaho, June 22, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc., a Massachusetts-based biopharmaceutical company, is seeking new sources of a plant commonly known as...
June 22, 2011 08:00 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Expands Clinical Development Program for IPI-926, an Oral Smoothened Antagonist Targeting the Hedgehog Pathway

CAMBRIDGE, Mass., June 22, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that it is expanding its clinical development program for IPI-926, a novel, oral small...
June 06, 2011 15:00 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Presents Data on Retaspimycin Hydrochloride, a Novel Hsp90 Inhibitor, in Non-Small Cell Lung Cancer at ASCO Meeting

CHICAGO, June 6, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced encouraging results from a Phase 1b trial of retaspimycin hydrochloride (HCl) (also known as...
June 04, 2011 09:00 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Reports Results From Phase 1b Clinical Trial of IPI-926, an Oral Smoothened Antagonist, in Pancreatic Cancer at ASCO Meeting

CHICAGO, June 4, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced encouraging results from the Phase 1b portion of an ongoing Phase 1b/2 clinical trial of IPI-926...
June 01, 2011 06:00 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity to Highlight Clinical Progress and Review Abstracts to be Presented at ASCO Annual Meeting

— Company to Host Webcast and Conference Call Today at 8:30 a.m. ET with Dr. Gregory Riely, Principal Investigator for Ongoing Phase 2 Trial of Retaspimycin HCl, a Novel...
May 31, 2011 08:00 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Pharmaceuticals to Present at Jefferies Conference

CAMBRIDGE, Mass., May 31, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) will be presenting at Jefferies Global Healthcare Conference on Wednesday, June 8, 2011 at 9:30 a.m. ET...

Next Page keyboard_arrow_right